Engineered T cells for pancreatic cancer treatment

HPB

Volumn 13, Issue 9, 2011, Pages 643-650

  Katari, Usha L ^a   Keirnan, Jacqueline M ^a   Worth, Anna C ^a   Hodges, Sally E ^b   Leen, Ann M ^a   Fisher, William E ^b   Vera, Juan F ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

chimeric antigen receptor; immunotherapy; pancreatic cancer; prostate stem cell antigen

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; OKT 3; PROSTATE STEM CELL ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; CANCER CELL; CANCER IMMUNOTHERAPY; CASE REPORT; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PANCREAS CANCER; RETROVIRUS; T LYMPHOCYTE;

EID: 80051875696     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2011.00344.x     Document Type: Conference Paper

References (31)

1. Sweeney AD, Wu MF, Hilsenbeck SG, Brunicardi FC, Fisher WE,. (2009) Value of pancreatic resection for cancer metastatic to the pancreas. J Surg Res 156: 189-198.
2. Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G, et al,. (2007) Complete responses of relapsed lymphoma following genetic modification of tumour-antigen presenting cells and T lymphocyte transfer. Blood 110: 2838-2845. (Pubitemid 350006936)
3. Matera L,. (2010) The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer. Cancer Treat Rev 36: 131-141.
4. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al,. (2008) Virus-specific T cells engineered to co-express tumour-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14: 1264-1270.
5. Vera J, Savoldo B, Vigouroux S, Biagi E, Pule M, Rossig C, et al,. (2006) T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 108: 3890-3897. (Pubitemid 44864573)
6. Rossig C, Brenner MK,. (2004) Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther 10: 5-18. (Pubitemid 38878144)
7. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, et al,. (2010) Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumour. Cancer Res 70: 9053-9061.
8. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M,. (2010) Treatment of chronic lymphocytic leukaemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 18: 666-668.
9. Vera JF, Brenner MK, Dotti G,. (2009) Immunotherapy of human cancers using gene modified T lymphocytes. Curr Gene Ther 9: 396-408.
10. Leen AM, Rooney CM, Foster AE,. (2007) Improving T cell therapy for cancer. Annu Rev Immunol 25: 243-265. (Pubitemid 46697909)
11. Raff AB, Gray A, Kast WM,. (2009) Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett 277: 126-132.
12. Barbisan F, Mazzucchelli R, Santinelli A, Scarpelli M, Lopez-Beltran A, Cheng L, et al,. (2010) Expression of prostate stem cell antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer. Histopathology 57: 572-579.
13. Vera JF, Brenner LJ, Gerdemann U, Ngo MC, Sili U, Liu H, et al,. (2010) Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother 33: 305-315.
14. Leyton JV, Olafsen T, Lepin EJ, Hahm S, Bauer KB, Reiter RE, et al,. (2008) Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumours. Clin Cancer Res 14: 7488-7496.
15. Leyton JV, Olafsen T, Sherman MA, Bauer KB, Aghajanian P, Reiter RE, et al,. (2009) Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumours. Protein Eng Des Sel 22: 209-216.
16. Vera JF, Hoyos V, Savoldo B, Quintarelli C, Giordano Attianese GM, Leen AM, et al,. (2009) Genetic manipulation of tumour-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther 17: 880-888.
17. Quintarelli C, Vera JF, Savoldo B, Giordano Attianese GM, Pule M, Foster AE, et al,. (2007) Co-expression of cytokine and suicide genes to enhance the activity and safety of tumour-specific cytotoxic T lymphocytes. Blood 110: 2793-2802. (Pubitemid 350006931)
18. Leen AM, Sili U, Vanin EF, Jewell AM, Xie W, Vignali D, et al,. (2004) Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood 104: 2432-2440. (Pubitemid 39331844)
19. Wente MN, Jain A, Kono E, Berberat PO, Giese T, Reber HA, et al,. (2005) Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas 31: 119-125. (Pubitemid 41077139)
20. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al,. (2009) The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research. Clin Cancer Res 15: 5323-5337.
21. Gu Z, Yamashiro J, Kono E, Reiter RE,. (2005) Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumour growth in vivo via an Fc-independent mechanism. Cancer Res 65: 9495-9500. (Pubitemid 41508019)
22. Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC,. (2009) Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Mol Ther 17: 1101-1108.
23. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al,. (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12: 6106-6115. (Pubitemid 44703776)
24. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, et al,. (2006) Treatment of metastatic renal cell carcinoma with autologous T lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24: 20-22.
25. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA,. (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18: 843-851.
26. Heslop HE,. (2010) Safer CARS. Mol Ther 18: 661-662.
27. Matsueda S, Yao A, Ishihara Y, Ogata R, Noguchi M, Itoh K, et al,. (2004) A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patients. Prostate 60: 205-213. (Pubitemid 38971832)
28. Matsueda S, Kobayashi K, Nonaka Y, Noguchi M, Itoh K, Harada M,. (2004) Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer. Cancer Immunol Immunother 53: 479-489. (Pubitemid 38680254)
29. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al,. (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854. (Pubitemid 35231542)
30. Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, et al,. (2001) Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 24: 363-373. (Pubitemid 32825868)
31. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al,. (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129. (Pubitemid 44547756)